Group 1 - The stock of Frontline Bio (688221.SH) closed at 18.25 yuan, with a decline of 4.4%, currently in a state of breaking issue [1] - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total share capital after issuance, at a price of 20.50 yuan per share [1][2] - The total amount raised from the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan, intended for various clinical research projects and working capital [2][4] Group 2 - The highest stock price of Frontline Bio on the listing day was 35.53 yuan, marking the peak since its listing [2] - The underwriting and sponsorship fees for the initial public offering amounted to 12.689 million yuan, with the underwriting and sponsorship fee being 11.613 million yuan [2] - The actual controller of Frontline Bio is Dong Xie, who holds U.S. nationality and has permanent residency in China [3]

Core Viewpoint - Wankai New Materials (301216.SZ) is currently experiencing a decline in stock price, closing at 15.94 yuan with a drop of 3.57%, indicating a state of being below its initial public offering price [1] Group 1: Initial Public Offering and Financials - Wankai New Materials was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on March 29, 2022, with an initial public offering of 85.85 million shares at a price of 35.68 yuan per share [1] - The total funds raised from the IPO amounted to 3.063 billion yuan, with a net amount of 2.915 billion yuan after expenses, exceeding the planned fundraising by 1.411 billion yuan [1] - The company intended to use the raised funds for projects including a 1.2 million ton food-grade PET polymer material project (Phase II), a multifunctional green and environmentally friendly polymer material project, and to supplement working capital [1] Group 2: Subsequent Financial Activities - The total issuance costs for the IPO were 148 million yuan, with underwriting and sponsorship fees accounting for 123 million yuan [2] - On May 31, 2023, Wankai New Materials announced a dividend plan, distributing 3 yuan (pre-tax) for every 10 shares and a bonus issue of 5 shares [2] - The company plans to issue convertible bonds with a total fundraising amount not exceeding 2.7 billion yuan, which will be used for a 1.2 million ton MEG project and to supplement working capital, with the listing date set for September 5, 2024 [2][3]

中国经济网北京8月18日讯ST中装（002822）(002822.SZ)今日收报3.52元，跌幅1.95%。该股目前处于 破发状态。 ST中装于2016年11月29日在深圳证券交易所上市，公开发行股票7,500万股，发行价格为10.23元/股，保 荐机构(主承销商)为国海证券股份有限公司，保荐代表人为陈贤德、关建宇。 ST中装首次公开发行股票募集资金总额为76,725.00万元，募集资金净额为67,603.20万元。ST中装最终 募集资金净额比原计划少31.77万元。ST中装招股说明书显示，该公司拟募集资金67,634.97亿元，分别 用于部品部件工厂化生产项目、营销中心建设项目、设计研发中心建设项目、信息化系统建设项目、补 充公司流动资金。 ST中装首次公开发行股票的发行费用总额为9,121.80万元，其中，保荐及承销费7,100万元。 据ST中装年度募集资金使用情况专项说明，公司2019年公开发行可转换公司债券的募集资金情况为， 经中国证券监督管理委员会"证监许可[2018]1911号"文核准，中装建设公司获准公开发行面值总额为人 民币525,000,000.00元可转换公司债券，期限6年，募集资金总额为 ...

Core Viewpoint - The specific shareholder, Hangzhou Guangfeng Qiwo Equity Investment Partnership, plans to reduce its holdings in Heshun Technology by up to 655,300 shares, representing 0.8191% of the total share capital, over a three-month period starting from September 4, 2025 [1][2]. Group 1 - The reduction will occur through centralized bidding or block trading, with a limit of 655,300 shares within any continuous 90-day period [1]. - As of the announcement date, Guangfeng Qiwo holds 655,300 shares, making it the fifth largest shareholder of Heshun Technology [2]. - The implementation of this reduction plan will not lead to a change in the company's control or affect its ongoing operations [3]. Group 2 - Heshun Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on March 23, 2022, with an initial public offering of 20 million shares at a price of 56.69 yuan per share [3]. - The company raised a total of 1.134 billion yuan, with a net amount of 1.018 billion yuan after expenses, exceeding the original fundraising plan by 403 million yuan [4]. - The funds raised are intended for the construction of a polyester film production base, a research and development center, and to supplement working capital [4].

Core Points - The company Xi Di Wei (688173.SH) announced a share reduction plan by its Vice President and core technical personnel Fan Jun, who intends to sell up to 3,000,000 shares, representing no more than 0.73% of the total share capital, within three months after the announcement [1] - As of the announcement date, Fan Jun holds 13,049,225 shares, accounting for 3.18% of the total share capital, all of which are unrestricted shares obtained before the company's IPO [1] - The company has no controlling shareholder, with actual controllers being Dai Zuyu, Tao Hai, and Tang Ya [1] Company Background - Xi Di Wei was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 21, 2022, with an initial public offering of 40.01 million shares at a price of 33.57 yuan per share [2] - The stock reached a peak price of 51.88 yuan on its first trading day but is currently in a state of decline [3] - The total funds raised from the IPO amounted to 1.343 billion yuan, with a net amount of 1.221 billion yuan after deducting issuance costs, exceeding the original plan by 640 million yuan [3] Fund Utilization - The funds raised are intended for various projects, including the development and industrialization of high-performance power management chips for consumer electronics and communication devices, as well as new-generation automotive and industrial power management chips [3] - The total issuance costs for the IPO were 122 million yuan, with underwriting and sponsorship fees amounting to 102 million yuan [4]

Group 1 - Tianyue Advanced Technology Co., Ltd. (天岳先进) plans to list its H-shares on the Hong Kong Stock Exchange starting August 19, 2025, with a maximum offering price of HKD 42.80 per share [1] - The company intends to issue a total of 47,745,700 H-shares, with 2,387,300 shares available for public offering in Hong Kong and 45,358,400 shares for international offering [1] - Assuming the offering price of HKD 42.80 per share, the estimated net proceeds from the global offering will be approximately HKD 1,938.1 million, after deducting underwriting commissions and other estimated expenses [1] Group 2 - Tianyue Advanced was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 12, 2022, with an initial offering price of CNY 82.79 per share and a total of 42,971,100 shares issued [2] - The company is currently in a state of share price decline (破发状态) [2] - The total funds raised from the initial public offering amounted to CNY 35.58 billion, with a net amount of CNY 32.03 billion after deducting issuance costs, exceeding the original plan by CNY 1.203 billion [2] Group 3 - The total issuance costs for the initial public offering were CNY 354 million, with underwriting and sponsorship fees amounting to CNY 319 million [3]

中国经济网北京8月5日讯 海天味业（603288）（03288.HK）港股今日收报33.36港元，跌幅1.71%，创 上市以来收盘价新低。目前该股H股处于破发状态。 海天味业6月19日在港交所上市，当日盘中最低报36.05港元，跌幅0.69%，一度跌破发行价。最终发售 价及配发结果公告显示，海天味业全球发售项下的发售股份数目为279,031,700股H股（经计及发售量调 整权获悉数行使及视乎超额配股权行使与否而定），香港发售股份数目为55,279,900股H股（经重新分 配后调整），国际发售股份数目为223,751,800股H股（经计及发售量调整权获悉数行使、经重新分配后 调整以及视乎超额配股权行使与否而定）。 以今日收盘价33.36港元计算，较36.30港元的发行价已下跌8.1%，高瓴HHLR Advisors与HSG Growth （红杉中国）均浮亏。 海天味业的联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人为中国国际 金融香港证券有限公司、高盛（亚洲）有限责任公司、摩根士丹利亚洲有限公司，联席账簿管理人及联 席牵头经办人为中银国际亚洲有限公司、工银国际证券有限公司、交银国际证券有 ...

Group 1 - The stock price of Arctech (688472.SH) fell by 3.56% to 8.93 yuan as of the market close on July 31, 2023, indicating that the stock is currently in a state of decline since its IPO [1] - Arctech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 9, 2023, with an initial public offering (IPO) price of 11.10 yuan per share. The total number of shares issued before the full exercise of the over-allotment option was 541,058,824 shares, accounting for 15.00% of the total share capital post-issue [1] - After the full exercise of the over-allotment option, the total number of shares issued increased to 622,217,324 shares, representing 16.87% of the total share capital post-issue [1][2] Group 2 - The total amount of funds raised from the IPO was 600,575.29 million yuan before the exercise of the over-allotment option and 690,661.23 million yuan after the full exercise [1][2] - The net amount raised after deducting issuance costs was 572,782.43 million yuan before the over-allotment option and 662,845.46 million yuan after the full exercise [1][2] - The final net amount raised exceeded the original plan by 172,782.43 million yuan before the over-allotment option and 262,845.46 million yuan after the full exercise [2] Group 3 - The total issuance costs for the IPO were 27,792.86 million yuan before the over-allotment option and 27,815.77 million yuan after the full exercise, with underwriting and sponsorship fees amounting to 17,264.15 million yuan [3] - The actual controllers of Arctech are Xiaohua Qu and his spouse Han Bing Zhang, both of whom hold Canadian nationality [4]

Core Points - Junshi Bioscience's stock closed at 39.12 yuan, down 4.59% [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, with an initial offering price of 55.50 yuan per share [1] - The stock reached a peak of 220.40 yuan on its first trading day but has since experienced a significant decline, currently trading below its initial offering price [1] Fundraising and Financials - Junshi Bioscience raised a total of 4.836 billion yuan in its initial public offering (IPO), with a net amount of 4.497 billion yuan after deducting issuance costs, exceeding the planned amount by 1.797 billion yuan [1] - The company planned to use the raised funds for innovative drug research and development, a technology industrialization project, repaying bank loans, and supplementing working capital [1] - In 2022, the company issued 70 million A-shares at a price of 53.95 yuan per share, raising approximately 3.776 billion yuan, with a net amount of about 3.745 billion yuan after expenses [2] - The total amount raised by Junshi Bioscience from both IPOs is approximately 8.612 billion yuan [2] Profitability - From 2016 to 2024, the company's net profit attributable to shareholders has shown consistent losses, with figures ranging from -1.35 billion yuan in 2016 to -12.81 billion yuan in 2024 [3] - The net profit excluding non-recurring gains and losses also reflects significant losses, with values from -1.60 billion yuan in 2016 to -12.90 billion yuan in 2024 [3]

Core Viewpoint - The announcement reveals that shareholders of Saiwei Microelectronics (688325.SH) plan to reduce their holdings through a share transfer agreement, with a total of up to 15,505,310 shares (approximately 18.00% of the total share capital) to be transferred within six months from the announcement date [1] Group 1: Shareholder Reduction Plans - Wu Yuefeng Investment and its action group, including Beijing Yihe and Shanghai Lingguan, plan to reduce their holdings by a total of up to 15,505,310 shares [1] - Wu Yuefeng Investment intends to reduce its holdings by up to 9,778,735 shares (approximately 11.35% of the total share capital) from July 30, 2025, to January 29, 2026, due to personal funding needs [2] - Beijing Yihe plans to reduce its holdings by up to 3,348,874 shares (approximately 3.89% of the total share capital) during the same period for similar funding reasons [2] - Shanghai Lingguan aims to reduce its holdings by up to 2,377,701 shares (approximately 2.76% of the total share capital) within the same timeframe [2] Group 2: Company Background and Financials - Saiwei Microelectronics was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 22, 2022, with an initial offering price of 74.55 yuan per share [3] - The stock opened at 52.33 yuan on its first trading day, reflecting a decline of 29.81%, and has remained below the initial offering price [3] - The company raised a total of 1.491 billion yuan, with a net fundraising amount of 1.355 billion yuan, exceeding the original plan by 546 million yuan [4] - The funds raised are allocated for various projects, including battery management and power management chip development for consumer electronics and industrial applications, as well as working capital [5]